Suggested remit - To appraise the clinical and cost effectiveness of ropeginterferon alfa-2b within its marketing authorisation for treating polycythaemia vera without symptomatic splenomegaly
Status In progress
Process STA 2018
ID number 1596

Provisional Schedule

Expected publication 02 December 2020

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
27 June 2019 As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly. Please note that following on from advice received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late January 2020. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust evidence submission
17 May 2019 - 17 June 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
09 May 2019 In progress, Referred 29 April 2019

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance